These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 17113714)

  • 1. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of CYP450 testing in the clinical setting.
    Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
    Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
    Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
    Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
    Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.
    Rogers JF; Nafziger AN; Bertino JS
    Am J Med; 2002 Dec; 113(9):746-50. PubMed ID: 12517365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
    Quaranta S; Dupouey J; Colle R; Verstuyft C
    Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
    Seeringer A; Kirchheiner J
    Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
    Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
    J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine.
    Oscarson M
    Clin Chem Lab Med; 2003 Apr; 41(4):573-80. PubMed ID: 12747605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
    Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B; Wang J; Huang SQ; Su HH; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing relevance of pharmacogenetics of drug metabolism in clinical practice.
    Pillans PI
    Intern Med J; 2001 Nov; 31(8):476-8. PubMed ID: 11720061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
    Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
    Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of cardiovascular pharmacogenetics.
    Voora D; Ginsburg GS
    J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
    Ingelman-Sundberg M; Sim SC
    Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.